Dear Colleagues,
Over the last several decades, heart failure (HF) treatment has made considerable strides. In patients affected by HF with reduced left ventricular ejection fraction (HFrEF), neuro-hormonal modulation by angiotensin receptor neprilysin inhibitors, beta-blockers and mineralocorticoid receptor antagonists along with cardiorenal protection by type 2 sodium–glucose cotransporter inhibitors (SGLT2i) are currently recommended in order to modify the clinical course of this entity and improve life expectancy. Aside from these 4 classes of drugs, new molecules (e.g., vericiguat, omecamtiv mecarbil and ferric carboxymaltose) have recently been shown to be capable of further reducing hospitalization, thus making the HF therapeutic approaches even more complex. In this scenario, there is a need to better define how to tailor HFrEF medical treatment as well as how to evaluate therapeutic targets and patients’ responses.
Recent trials have demonstrated the efficacy of SGLT2i in improving outcome of HF patients with mildly reduced (HFmrEF) or preserved (HFpEF) left ventricular ejection fraction. Although these beneficial effects are proven, the mechanisms by which SGLT2i are able to improve prognosis throughout the whole range of left ventricular ejection fraction have not been fully clarified.
Finally, in patients affected by HFpEF, the research continues to study novel drugs for HF treatment, some of which have recently demonstrated the ability to target specific etiological mechanisms such as in hypertrophic cardiomyopathy of cardiac amyloidosis.
The Special Issue "Advances of Drug Therapy in Heart Failure" aims to collect high-quality original research papers and comprehensive reviews on recent evidence in relation to the therapeutic treatment of heart failure. The topics of interest include, but are not limited to:
• Acute and chronic heart failure
• Myocardial fibrosis/remodeling
• Cardiorenal syndrome and metabolism
• Cardiomyopathies
• Arrhythmias
• Cardiovascular imaging
• Genetics
• Pathophysiological mechanisms
• Biomarkers
Dr. Massimo Iacoviello
Guest Editor
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.